Big Money Sentiment increased to 2.39 in 2018 Q4. It has change of 0.81, from 2018Q3’s 1.58. The ratio improved due to AtriCure, Inc. positioning: 12 sold and 26 reduced. 39 funds amassed positions and 52 increased positions. Investors holded 27.72 million in 2018Q3 but now own 31.33 million shares or 13.02% more.
70,052 are owned by Wells Fargo And Mn. Parametric Lc reported 0% in AtriCure, Inc. (NASDAQ:ATRC). State Street has 0% invested in AtriCure, Inc. (NASDAQ:ATRC). 4,326 are held by First Quadrant Limited Partnership Ca. Citigroup invested in 11,042 shs or 0% of the stock. Quantbot Lp stated it has 0% of its capital in AtriCure, Inc. (NASDAQ:ATRC). Huntington Fincl Bank invested in 300 shs. Commerce Bancshares reported 0% in AtriCure, Inc. (NASDAQ:ATRC). Robeco Institutional Asset Management Bv stated it has 6,222 shs. Nuveen Asset Mngmt Limited Co accumulated 88,733 shs or 0.02% of the stock. Moreover, Barclays Pcl has 0% invested in AtriCure, Inc. (NASDAQ:ATRC). Regions invested in 1,251 shs. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 2,608 shs. Alphaone Inv Serv Limited Liability owns 133,286 shs for 1.69% of their capital. California-based Quantum has invested 2.24% in AtriCure, Inc. (NASDAQ:ATRC).

On April, 25 is anticipated AtriCure, Inc. (NASDAQ:ATRC)’s earnings report, RTT reports. Analysts predict $-0.19 earnings per share. That’s $0.12 up or 38.71 % from 2018’s earnings of $-0.31. Wall Street forecasts -9.52 % EPS growth as of April, 25. The stock increased 1.55% or $0.41 during the last trading session, touching $26.79.AtriCure, Inc. is uptrending after having risen 65.27% since April 1, 2018. ATRC has 220,199 volume or 0.15% up from normal. The stock outperformed the S&P500 by 60.90%.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Coverage

Total analysts of 2 have positions in AtriCure (NASDAQ:ATRC) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since October 9, 2018 according to StockzIntelligence Inc AtriCure has 3 analyst reports. The stock rating was maintained by Needham with “Buy” on Friday, March 1. The stock rating was maintained by Canaccord Genuity with “Buy” on Tuesday, October 9.

AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally.The firm is valued at $1.03 billion. The firm offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.Currently it has negative earnings. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set.

For more AtriCure, Inc. (NASDAQ:ATRC) news announced briefly go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “AtriCure Is An Interesting Buy In December 2018 – Seeking Alpha” announced on December 14, 2018, “AtriCure files for mixed shelf and sale of stock by current investors – Seeking Alpha” on March 01, 2019, “AtriCure misses by $0.04, beats on revenue – Seeking Alpha” with a publish date: February 28, 2019, “AtriCure launches cryoICE cryoSPHERE probe in U.S. – Seeking Alpha” and the last “ATRC Crosses Below Key Moving Average Level – Nasdaq” with publication date: March 04, 2019.